We advised Oruka Therapeutics on the transaction

Davis Polk advised Oruka Therapeutics in connection with its collaboration and license agreement with Halozyme Hypercon, Inc. (a wholly owned subsidiary of Halozyme Therapeutics, Inc.). Under the agreement, Oruka has licensed Halozyme’s Hypercon technology for use with ORKA 001, in development for psoriasis and related inflammatory diseases, and up to one additional target. Hypercon is an innovative microparticle technology that allows for hyperconcentration of drugs and biologics, reducing injection volume for a given dose and supporting more convenient, patient friendly administration. Oruka will make an upfront payment to Halozyme and potential future milestone payments. Halozyme will also be eligible to receive mid-single digit royalties on net sales of products using the Hypercon technology.

Oruka Therapeutics is a clinical-stage biopharmaceutical company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases.

Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies.

The Davis Polk IP and commercial transactions team included partner David R. Bauer, counsel Samantha Lefland and associate Hannah Coleman. Partner William A. Curran and associate Georgianna Eck provided tax advice. The antitrust and competition team included partner Arthur J. Burke and counsel Suzanne Munck af Rosenschold. Members of the Davis Polk team are based in the New York and Washington DC offices.

Copy link to share post